Satralizumab, previously known as SA-237 , represents a significant treatment for NMOSD and other inflammatory conditions . Recent studies have shown encouraging results regarding its effectiveness in preventing relapses and disease activity . Specifically , Phase III studies – including the ADA

Belimumab, marketed as LymphoStat B, represents a unique approach for autoimmune conditions, particularly lupus. This monoclonal antibody selectively binds to B cell activating factor, a key factor involved in immune cell development and harmful formation. By lowering BAFF levels, LymphoStat β ef